SMA Courses
 
Adjust font size :   fontsmall   fontbig
 
 

  

SMA CALENDAR

<October 2017>
MonTueWedThuFriSatSun
2526272829301
2345678
9101112131415
16171819202122
23242526272829
303112345
 
 

Medical Symposium


26 Aug 2017

Course Code:  FMD 3 - Medical Symposium
Time:  2:00 - 5:00 pm
Course Fees:  Complimentary for SMA members and $50 for non-SMA members
Venue: 

Marina Bay Sands, Heliconia Ballroom, Level 3, 10 Bayfront Avenue, Singapore 01895.,
 

  Dr Charles Tan Tse Kuang

In surgery, new technology has been developed to eliminate some problems that surgeons face during more challenging laparoscopic or conventional operations. Advanced surgical instruments including robotics and optics continue the trend of the smaller scar or better patient care.   This talk shares many of the current trends in surgical practice.

Dr Jacob Cheng Yen Chuan

Advancement in Ophthamology

 

Adj A/Prof John Chia Whay Kuang

Ovarian Cancer is no longer recognized as a single entity but comprising of at least 5 different cancers involving the ovary.  These subtypes - high grade serous (HGS), clear cell (CC), endometroid (E), mucinous(M) and low grade serous (LSG) - are characterized by differing cells of origin, pathogenesis, molecular aberrations, patterns of involvement and spread, response to chemotherapy, and prognosis – that qualify them as bona fide distinct tumors.  The advent of Next Generation Sequencing technology and routine sequencing of patient and tumor genomes in the clinic, is transforming the understanding and management of ovarian cancers. The Cancer Genome Atlas (TCGA) has underscored the role of the Homologous recombinant (HR) pathway (including BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, and RAD51D) in the pathogenesis of High grade serous ovarian cancer, and the mediation of tumor cell hypersensitivity to platinum chemotherapy and PARP inhibitors.  Olaparib, an oral PARP inhibitor has been shown to extend Progression free survival for more than 19 mths, with low or little toxicity, in recurrent ovarian cancer.  More recently, immunotherapy with immune checkpoint inhibitors have demonstrated potency and superior efficacy, vis a vis chemotherapy in melanoma, and selected lung cancers.   More than 20 studies of immune-checkpoints are currently being undertaken - as single agents, or in combination with chemotherapy and various other immune adjuvants – to define its role in Ovarian cancer.   It is virtually certain that the next 15 years will achieve major advances in the management of this lethal disease.